Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

被引：4

作者：

Wang, Jianxiang ^{[1
]}

Jiang, Bin ^{[2
]}

Li, Jian ^{[3
]}

Liu, Ligen ^{[4
]}

Du, Xin ^{[5
]}

Jiang, Hao ^{[6
]}

Hu, Jianda ^{[7
]}

Yuan, Menghe

Sakatani, Taishi ^{[8
]}

Kadokura, Takeshi ^{[9
]}

Takeuchi, Masato ^{[9
]}

Izuka, Shunsuke ^{[9
]}

Girshova, Larisa ^{[10
]}

Tan, Jerome ^{[11
]}

Bondarenko, Sergey N. ^{[12
]}

Wong, Lily L. L. ^{[13
]}

Khuhapinant, Archrob ^{[14
]}

Martynova, Elena ^{[15
]}

Hasabou, Nahla ^{[16
]}

Tiu, Ramon V. ^{[16
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Peking Univ Int Hosp, Dept Hematol, Beijing, Peoples R China

[3] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[4] Shanghai Tongren Hosp, Dept Hematol, Shanghai, Peoples R China

[5] Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China

[6] Peking Univ Peoples Hosp, Dept Hematol, Beijing, Peoples R China

[7] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Fuzhou, Fujian, Peoples R China

[8] Astellas Pharma Inc, Beijing, Peoples R China

[9] Astellas Pharma Inc, Tokyo, Japan

[10] Almazov Natl Med Res Ctr, St Petersburg, Russia

[11] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Dept Hematol,Ampang Hosp Selangor, Sarawak, Malaysia

[12] State Med Univ, Clin Res Inst Pediat Hematol & Transplantat Name, St Petersburg, Russia

[13] Queen Elizabeth Hosp, Dept Hematol, Kota Kinabalu, Sabah, Malaysia

[14] Mahidol Univ, Fac Med Siriraj Hosp, Div Hematol, Dept Med, Bangkok, Thailand

[15] Skolkovo Inst Sci & Technol, Moscow, Russia

[16] Astellas Pharma Inc, Northbrook, IL USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145436

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页数：4

共 50 条

[41] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
McMahon, Christine M.
Canaani, Jonathan
Rea, Bryan
Sargent, Rachel Lynn
Morrissette, Jennifer J. D.
Lieberman, David B.
Watt, Christopher
Schwartz, Gregory W.
Faryabi, Robert B.
Ferng, Timothy T.
Shah, Neil P.
Smith, Catherine C.
Carroll, Martin
Perl, Alexander E.
BLOOD, 2017, 130
[42] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
Chen, Nianci
Zhou, Yile
Tong, Hongyan
Wei, Juying
Lou, YinJun
Zhou, De
Fan, Cuihua
Huang, Li
Mao, Liping
Li, Chenying
Wang, Huafeng
Jin, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
Smith, Catherine C.
Levis, Mark J.
Perl, Alexander E.
Hill, Jason E.
Rosales, Matt
Bahceci, Erkut
BLOOD ADVANCES, 2022, 6 (07) : 2144 - 2155
[44] Midostaurin in FLT3-Mutated Acute Myeloid Leukemia
Sahoo, Ranjit K.
Kumar, Lalit
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1901 - 1902
[45] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Perl, Alexander E.
Martinelli, Giovanni
Cortes, Jorge E.
Neubauer, Andreas
Berman, Ellin
Paolini, Stefania
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Ustun, Celalettin
Fabbiano, Francesco
Di Stasi, Antonio
Stuart, Robert
Olin, Rebecca
Kasner, Margaret
Ciceri, Fabio
Chou, Wen-Chien
Podoltsev, Nikolai
Recher, Christian
Yokoyama, Hisayuki
Hosono, Naoko
Yoon, Sung-Soo
Lee, Je-Hwan
Pardee, Timothy
Fathi, Amir T.
Liu, Chaofeng
Liu, Xuan
Bahceci, Erkut
Levis, Mark J.
CANCER RESEARCH, 2019, 79 (13)
[46] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
Short, Nicholas J.
Daver, Naval
Dinardo, Courtney D.
Kadia, Tapan
Nasr, Lewis F.
Macaron, Walid
Yilmaz, Musa
Borthakur, Gautam
Montalban-Bravo, Guillermo
Garcia-Manero, Guillermo
Issa, Ghayas C.
Chien, Kelly S.
Jabbour, Elias
Nasnas, Cedric
Huang, Xuelin
Qiao, Wei
Matthews, Jairo
Stojanik, Christopher J.
Patel, Keyur P.
Abramova, Regina
Thankachan, Jennifer
Konopleva, Marina
Kantarjian, Hagop
Ravandi, Farhad
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
[47] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Numan, Yazan
Abdel Rahman, Zaid
Grenet, Justin
Boisclair, Stephanie
Bewersdorf, Jan Philipp
Collins, Cailin
Barth, Dylan
Fraga, Martina
Bixby, Dale L.
Zeidan, Amer M.
Yilmaz, Musa
Desai, Pankil
Mannis, Gabriel
Deutsch, Yehuda E.
Abaza, Yasmin
Dinner, Shira
Frankfurt, Olga
Litzow, Mark
Al-Kali, Aref
Foran, James M.
Sproat, Lisa Z.
Jovanovic, Borko
Daver, Naval
Perl, Alexander E.
Altman, Jessica K.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
[48] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
Chew, Serena
Mackey, Melissa C.
Jabbour, Elias
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
[49] Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia
Murray, Graeme
Bouligny, Ian Michael
Patel, Tilak
Doyel, Michael
Boron, Josh
Tran, Valerie
Gor, Juhi
Hang, Yiwei
Ho, Thuy
Zacholski, Kyle
Venn, Chad Michael
Alnimer, Yanal Mufeed
Wages, Nolan
Grant, Steven
Maher, Keri Renee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
Chen, Nianci
Pan, Jiajia
Zhou, Yile
Mao, Liping
Lou, Yinjun
Qian, Jiejing
Xu, Gaixiang
Wei, Juying
Zhou, De
Shou, Lihong
Li, Huang
Yan, Minchao
Zeng, Hui
Fan, Cuihua
Wu, Gongqiang
Feng, Weiying
Tong, Hongyan
Jin, Jie
Wang, Huafeng
BLOOD, 2023, 142

← 1 2 3 4 5 →